Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine

Mark A. Suckow, Elliot Rosen, William R. Wolter, Valerie Sailes, Randy Jeffrey, Martin Tenniswood

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Vaccination, as an approach to prostate cancer, has largely focused on immunotherapy utilizing specific molecules or allogeneic cells. Such methods are limited by the focused antigenic menu presented to the immune system and by immunotolerance to antigens recognized as "self". To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats. Immunocompetent Ncr-Foxn1<nu> mice were vaccinated with the GFT cell vaccine four times, 7 days apart. The control animals were either not vaccinated or vaccinated with media or glutaraldehyde-fixed PC346C human prostate cancer cells and adjuvant. About 8 days after the final boost, serum and spleens were harvested. The splenocytes were co-incubated with PC346C cells and then transplanted orthotopically into sygneneic immunodeficient nude mice. About 10 weeks later, the prostates were weighed and sampled for histolologic examination. The spleens were harvested from additional mice, and the splenocytes were cultured, either with or without pulsing by GFT cells, and the supernatants harvested 72 h later for cytokine analysis. Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-α, IL-2, IFN-γ and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity. In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.

Original languageEnglish
Pages (from-to)1275-1283
Number of pages9
JournalCancer Immunology Immunotherapy
Volume56
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Prostatic Neoplasms
Vaccines
Growth
Immunity
Glutaral
Cytokines
Nude Mice
Prostate
Vaccination
Spleen
Seminal Vesicles
Interleukin-12
Serum
Interleukin-4
Interleukin-10
Immunotherapy
Interleukin-2
Wistar Rats
Immune System
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. / Suckow, Mark A.; Rosen, Elliot; Wolter, William R.; Sailes, Valerie; Jeffrey, Randy; Tenniswood, Martin.

In: Cancer Immunology Immunotherapy, Vol. 56, No. 8, 08.2007, p. 1275-1283.

Research output: Contribution to journalArticle

Suckow, Mark A. ; Rosen, Elliot ; Wolter, William R. ; Sailes, Valerie ; Jeffrey, Randy ; Tenniswood, Martin. / Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. In: Cancer Immunology Immunotherapy. 2007 ; Vol. 56, No. 8. pp. 1275-1283.
@article{0ecf5ee22cdb42f0ba0c474336a4dd9b,
title = "Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine",
abstract = "Vaccination, as an approach to prostate cancer, has largely focused on immunotherapy utilizing specific molecules or allogeneic cells. Such methods are limited by the focused antigenic menu presented to the immune system and by immunotolerance to antigens recognized as {"}self{"}. To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats. Immunocompetent Ncr-Foxn1 mice were vaccinated with the GFT cell vaccine four times, 7 days apart. The control animals were either not vaccinated or vaccinated with media or glutaraldehyde-fixed PC346C human prostate cancer cells and adjuvant. About 8 days after the final boost, serum and spleens were harvested. The splenocytes were co-incubated with PC346C cells and then transplanted orthotopically into sygneneic immunodeficient nude mice. About 10 weeks later, the prostates were weighed and sampled for histolologic examination. The spleens were harvested from additional mice, and the splenocytes were cultured, either with or without pulsing by GFT cells, and the supernatants harvested 72 h later for cytokine analysis. Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-α, IL-2, IFN-γ and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity. In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.",
author = "Suckow, {Mark A.} and Elliot Rosen and Wolter, {William R.} and Valerie Sailes and Randy Jeffrey and Martin Tenniswood",
year = "2007",
month = "8",
doi = "10.1007/s00262-006-0278-8",
language = "English",
volume = "56",
pages = "1275--1283",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine

AU - Suckow, Mark A.

AU - Rosen, Elliot

AU - Wolter, William R.

AU - Sailes, Valerie

AU - Jeffrey, Randy

AU - Tenniswood, Martin

PY - 2007/8

Y1 - 2007/8

N2 - Vaccination, as an approach to prostate cancer, has largely focused on immunotherapy utilizing specific molecules or allogeneic cells. Such methods are limited by the focused antigenic menu presented to the immune system and by immunotolerance to antigens recognized as "self". To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats. Immunocompetent Ncr-Foxn1 mice were vaccinated with the GFT cell vaccine four times, 7 days apart. The control animals were either not vaccinated or vaccinated with media or glutaraldehyde-fixed PC346C human prostate cancer cells and adjuvant. About 8 days after the final boost, serum and spleens were harvested. The splenocytes were co-incubated with PC346C cells and then transplanted orthotopically into sygneneic immunodeficient nude mice. About 10 weeks later, the prostates were weighed and sampled for histolologic examination. The spleens were harvested from additional mice, and the splenocytes were cultured, either with or without pulsing by GFT cells, and the supernatants harvested 72 h later for cytokine analysis. Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-α, IL-2, IFN-γ and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity. In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.

AB - Vaccination, as an approach to prostate cancer, has largely focused on immunotherapy utilizing specific molecules or allogeneic cells. Such methods are limited by the focused antigenic menu presented to the immune system and by immunotolerance to antigens recognized as "self". To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats. Immunocompetent Ncr-Foxn1 mice were vaccinated with the GFT cell vaccine four times, 7 days apart. The control animals were either not vaccinated or vaccinated with media or glutaraldehyde-fixed PC346C human prostate cancer cells and adjuvant. About 8 days after the final boost, serum and spleens were harvested. The splenocytes were co-incubated with PC346C cells and then transplanted orthotopically into sygneneic immunodeficient nude mice. About 10 weeks later, the prostates were weighed and sampled for histolologic examination. The spleens were harvested from additional mice, and the splenocytes were cultured, either with or without pulsing by GFT cells, and the supernatants harvested 72 h later for cytokine analysis. Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-α, IL-2, IFN-γ and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity. In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=34248573627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248573627&partnerID=8YFLogxK

U2 - 10.1007/s00262-006-0278-8

DO - 10.1007/s00262-006-0278-8

M3 - Article

C2 - 17242926

AN - SCOPUS:34248573627

VL - 56

SP - 1275

EP - 1283

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 8

ER -